hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06348030, orgStudyIdInfo id: 17401, briefTitle: Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: St. Joseph's Healthcare Hamilton, class: OTHER, descriptionModule briefSummary: Robotic-assisted thoracoscopic surgery (RTS) is safe and effective for patients with early-stage non-small cell lung cancer (NSCLC). During RTS, division, dissection, and sealing of lung tissue, bronchi, and blood vessels can be performed using handheld staplers with assistance from a bedside surgeon (Surgeon-Assisted), or totally robotically with robotic staplers and energy devices by the console surgeon (Totally Robotic). Totally Robotic lung resection enables the operating surgeon to perform the case independently, but its implication on costs and patient outcomes remains unknown. There also is, however, a lack of prospective research evaluating the costs of the two methods for dissection and vessel sealing in RTS. This RCT aims to evaluate the costs and perioperative patient outcomes of Totally Robotic lung resection using the Vessel Sealer Extend energy device (for vessels \<7mm) and the SureForm robotic stapler (Intervention) versus Surgeon-Assisted robotic lung resection using the Signia stapler (Control) during RTS for NSCLC using the da Vinci system., conditionsModule conditions: Lung Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Medtronic Signia Stapler, interventions name: Vessel Sealer Extend Energy Device and SureForm Stapler, outcomesModule primaryOutcomes measure: Costs of Totally Robotic versus Surgeon-Assisted Robotic Lung Resection, secondaryOutcomes measure: Operating Room Time, secondaryOutcomes measure: Length of Stay in Hospital, secondaryOutcomes measure: Duration of Chest Tube, secondaryOutcomes measure: Intraoperative Complications and Adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St. Joseph's Healthcare Hamilton, city: Hamilton, state: Ontario, zip: L8N 4A6, country: Canada, contacts name: Yogita S Patel, BSc, role: CONTACT, phone: 905-522-1155, phoneExt: 35096, email: patelys@mcmaster.ca, contacts name: Waël C Hanna, MDCM, MBA, FRCSC, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.25011, lon: -79.84963, hasResults: False
protocolSection identificationModule nctId: NCT06348004, orgStudyIdInfo id: 2024IIT-0125, briefTitle: The Association Between Albumin Administration and Short-term Rebleeding Risk in Cirrhosis Patients With Acute Variceal Hemorrhage and Stable Hemodynamics, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, descriptionModule briefSummary: The impact of albumin administration in cirrhotics with acute variceal hemorrhage (AVH) is controversial. We aim to investigate the short-term rebleeding risk associated with albumin administration in a retrospective study of hospitalized cirrhotics with AVH with stable hemodynamics. This retrospective analysis includes clinical data of cirrhosis patients with acute variceal bleeding admitted to our hospital from January 2021 to October 2023. Propensity score matching will be performed to account for potential confounders associated with albumin use for outcome analysis. According to the outcome, patients will be divided into rebleeding group and non-rebleeding group. To investigate the impact of albumin infusion on the rebleeding risk in the propensity-matched cohort, patients will be divided into albumin user group and albumin non-user group. The primary outcome is the rebleeding risk within 30 days after discharge., conditionsModule conditions: Cirrhosis, conditions: Acute Variceal Haemorrhage, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: The rebleeding risk within 30 days after discharge., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital, Zhejiang University School of Medicine, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06347991, orgStudyIdInfo id: Pro00140155, briefTitle: Alberta Chiropractic SelfBack Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: University of Alberta, class: OTHER, collaborators name: Chiropractic Association of Alberta, descriptionModule briefSummary: Recurrent and persistent low back pain (LBP) is a massive problem in Canada that causes a substantial pain, disability, cost, and even premature death.The good news is that treatments for recurrent and persistent LBP are available. Many guidelines now recommend education and exercise as the best intervention for chronic LBP. Unfortunately, education and exercise programs are not publicly funded in Canada-only Canadians with extended health benefits can access these programs.As a result, the 50% of Canadians who do not have extended health benefits often seek care for LBP from their publicly funded physicians. Physicians, in turn, have little choice but to reach for what they have available, including opioids, x-rays and referrals to specialists. Not only are these interventions unhelpful for chronic LBP, they are often harmful, sometimes deadly, and disproportionately affect lower socio-economic status households.A possible solution to this problem exists in a validated app (SelfBack) that provides tailored self-management plans consisting of advice on physical activity, physical exercises, and educational content. Tailoring of treatment plans to individuals is achieved by using case-based reasoning (CBR) methodology which is a branch of artificial intelligence.This study will evaluate the feasibility of distributing the SelfBack app to persons experiencing LBP through their chiropractors.The results of this study will help us understand the barriers and facilitators of distributing and using the app through Alberta Chiropractors. This information will be used to apply for funding for a larger study to understand the effectiveness of the app as an intervention for persistent and recurrent LBP., conditionsModule conditions: Chronic Low-back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: SelfBack, outcomesModule primaryOutcomes measure: The percentage of patients who utilize the SelfBack app, secondaryOutcomes measure: The percentage of clinicians who utilize the SelfBack app, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06347978, orgStudyIdInfo id: 24-41296, briefTitle: Personalized DBS for OCD Guided by Stereoencephalography Mapping, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2028-04, completionDateStruct date: 2028-04, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Andrew Moses Lee, MD, PhD, class: OTHER, descriptionModule briefSummary: This is a double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of 4-lead DBS surgery with bilateral IPGs and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment., conditionsModule conditions: Obsessive-Compulsive Disorder, conditions: OCD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Deep Brain Stimulation, outcomesModule primaryOutcomes measure: Primary Feasibility Endpoint #1 - Stimulation Target That Acutely Improves OCD Symptoms, primaryOutcomes measure: Primary Feasibility Endpoint #2 - Identifying an electrophysiological biomarker of OCD, primaryOutcomes measure: Primary Feasibility Endpoint #3 - Acute Symptomatic Improvement, primaryOutcomes measure: Primary Feasibility Endpoint #4 - Completion of Stages 1 and 2, primaryOutcomes measure: Primary Safety Endpoint - Serious Adverse Events, primaryOutcomes measure: Primary Efficacy Endpoint - Treatment Response, secondaryOutcomes measure: Secondary Efficacy Endpoint #1 - Improvement in YBOCS scores from Baseline, secondaryOutcomes measure: Secondary Efficacy Endpoint #2 - Improvement in OCD Symptoms from Baseline, secondaryOutcomes measure: Secondary Efficacy Endpoint #3 - Improvement in Depression Symptoms from Baseline, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Francisco, city: San Francisco, state: California, zip: 94143, country: United States, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False
protocolSection identificationModule nctId: NCT06347965, orgStudyIdInfo id: IIT20220541B-R1, briefTitle: Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2024-02-20, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Xin Wang, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to verify the effectiveness and safety of the low load blood flow restriction training program. The intervention effect, tolerance and compliance of low load blood flow restriction training and progressive resistance training on lung cancer patients complicated with sarcopenia during chemotherapy will be compared, in order to provide new ideas for improving or reversing sarcopenia.The main questions it aims to answer are:Can low load blood flow restriction training improve sarcopenia in chemotherapy induced lung cancer patients? Which training method is more effective and tolerable between low load blood flow restriction training and progressive resistance training?Participants will be randomly divided into 3 groups：1. Routine care group (Control group, CON): The researchers will provide participants with regular exercise and dietary guidance.2. Low load blood flow restriction group (LL-BFRT): The researchers will provide participants with a low load blood flow restriction training program constructed by our research group.3. Progressive resistance training group (PRE): The researchers will provide participants with progressive resistance training., conditionsModule conditions: Sarcopenia, conditions: Lung Neoplasms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 104, type: ACTUAL, armsInterventionsModule interventions name: Low load blood flow restriction training, interventions name: Progressive resistance training group, outcomesModule primaryOutcomes measure: Grip strength, primaryOutcomes measure: Appendicular Skeletal Muscle Index (ASMI), primaryOutcomes measure: Step speed, secondaryOutcomes measure: Body mass index (BMI), secondaryOutcomes measure: Quality of life for lung cancer patients, secondaryOutcomes measure: Exercise compliance, secondaryOutcomes measure: Exercise safety, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital, Zhejiang University School of Medicine, city: HangZhou, state: Zhejiang, zip: 310020, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06347952, orgStudyIdInfo id: SE1188, briefTitle: Mapping Arterial Perforators Within the Breast During Mammoplasty, acronym: Map-total, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-04-27, primaryCompletionDateStruct date: 2024-01-25, completionDateStruct date: 2024-01-29, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Royal Marsden NHS Foundation Trust, class: OTHER, descriptionModule briefSummary: Breast cancer surgery can often be carried out as part of a breast reduction procedure known as 'therapeutic mammoplasty'. Where a woman has a breast with adequate volume, even larger cancers can be removed in an aesthetically acceptable way with re-shaping of the breast (often reduction and lift) incorporated into the cancer removal. An expectation and desire for most women is that the nipple and areola (known as the 'nipple-areolar complex' or NAC) is not only preserved, but re-positioned (usually lifted) to re-balance the overall aesthetic result.In moving the NAC, the surgeon must ensure an adequate blood supply is maintained to preserve nourishment of the NAC tissue otherwise it can die (necrose) resulting in its removal. The tissue carrying the blood supply is known as a 'pedicle' and is fashioned by the surgeon for each patient during surgery.We know as surgeons, that in most areas of anatomy of the human body there are variations in the pattern of blood vessels. The NAC blood supply is no exception. Yet for each individual patient, the only way to safely know these anatomical patterns is to map them before or during surgery.A surgical tool utilising an aspect of ultrasound (known as doppler) is often used to locate visually (or by hearing) blood flow from blood vessels in operations where such knowledge is critical to the success of the procedure (for example DIEP-based breast reconstruction or chest wall perforator flaps).We would like to evaluate the effectiveness of the routine use of doppler for NAC preservation during mammoplasty procedures to see if it gives the consultant surgeon and/or trainee a greater degree of confidence when shaping the NAC pedicle to preserve its blood supply.In addition, we evaluate the training potential of patients undergoing symmetrising breast reduction, whereby the tissue removed is first mapped using acoustic doppler as for the NAC above., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ACTUAL, armsInterventionsModule interventions name: Use of Acoustic and color imaging doppler during surgery for breast cancer, outcomesModule primaryOutcomes measure: Full-thickness (complete or partial) necrosis of nipple-areolar complex, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Royal Marsden - Surrey, city: Sutton, state: England, zip: SM2 5PT, country: United Kingdom, geoPoint lat: 51.35, lon: -0.2, hasResults: False
protocolSection identificationModule nctId: NCT06347939, orgStudyIdInfo id: 2023-06638-01, briefTitle: Mediastinal EBUS Cryobiopsy Study In Sweden, acronym: MECRIS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Region Skane, class: OTHER, descriptionModule briefSummary: This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other. The investigators conduct EBUS TBNA and EBUS TBMCB on all the study participants.The cryobiopsy samples are numbered to evaluate the number of biopsies needed to reach a definite diagnosis and to assess the added value of every sample taken from the same participitant. Every participitant's own samples are compared to each other and added value of EBUS TBMCB is defined as the difference in diagnostic yield between the EBUS TBNA alone and the combination of EBUS TBNA with EBUS TBMCB. Diagnostic yield is defined as the efficacy of the investigation module in reaching a definite diagnosis (percentage of cases with a definite diagnosis).Follow up four weeks after the procedure to assess the risk for postoperative complications., conditionsModule conditions: Mediastinal Lymphadenopathy, conditions: Lung Cancer, conditions: Sarcoidosis, conditions: Lymphoma, conditions: Tuberculosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Mediastinal lymph nodes cryobiopsies, outcomesModule primaryOutcomes measure: Number of mediastinal cryobiopsies needed per patient to lead to a definite diagnosis., secondaryOutcomes measure: Adequacy of mediastinal cryobiopsies for PDL1 analysis in lung cancer., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Respiratory medicine and allergy department, Skåne University Hospital, status: RECRUITING, city: Lund, country: Sweden, contacts name: Hamid Akbarshahi, MD, PhD, role: CONTACT, phone: 004646171000, email: hamid.akbarshahi@med.lu.se, geoPoint lat: 55.70584, lon: 13.19321, locations facility: Norrlands universitetssjukhus, status: RECRUITING, city: Umeå, country: Sweden, contacts name: Annelie Behndig, MD, PhD, role: CONTACT, phone: 0907850000, email: annelie.behndig@umu.se, geoPoint lat: 63.82842, lon: 20.25972, hasResults: False
protocolSection identificationModule nctId: NCT06347900, orgStudyIdInfo id: Soh-Med-23-09-7PD, briefTitle: Corneal Topographic Changes in Different Grades of OSA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: Corneal topographic parameters in different degrees of obstructive sleep apnea, conditionsModule conditions: Corneal Ectasia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Pentacam (corneal topographic changes detection), Polysymnography, outcomesModule primaryOutcomes measure: Keratometric readings in diopters, corneal thickness in um, average progression index value, anterior and posterior corneal elevation values., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ophthalmology department, Sohag University, status: RECRUITING, city: Sohag, zip: 82511, country: Egypt, contacts name: Elshimaa A.Mateen, role: CONTACT, phone: 0201282223427, email: elshimaa.moussa@yahoo.com, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06347887, orgStudyIdInfo id: SGI-PCR-01, briefTitle: Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-31, primaryCompletionDateStruct date: 2024-01-16, completionDateStruct date: 2024-01-16, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Singlera Genomics Inc., class: INDUSTRY, descriptionModule briefSummary: The DNA methylation targets in preoperative plasma samples of the subjects will be detected by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by compared with the clinical diagnosis evidence., conditionsModule conditions: Colorectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1965, type: ACTUAL, armsInterventionsModule interventions name: ColonAiQ test and Colonoscopy, outcomesModule primaryOutcomes measure: Sensitivity for colorectal cancer with ColonAiQ test, primaryOutcomes measure: Specificity for colorectal cancer with ColonAiQ test, secondaryOutcomes measure: PPV for colorectal cancer with ColonAiQ test, secondaryOutcomes measure: NPV for colorectal cancer with ColonAiQ test, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Affiliated Hospital of Xuzhou Medical University, city: Xuzhou, state: Jiangsu, zip: 221000, country: China, geoPoint lat: 34.18045, lon: 117.15707, locations facility: The First Affiliated Hospital of Shandong First Medical University, city: Jinan, state: Shandong, zip: 250000, country: China, geoPoint lat: 36.66833, lon: 116.99722, locations facility: Shanxi Provincial People's Hospital, city: Taiyuan, state: Shanxi, zip: 030012, country: China, geoPoint lat: 37.86944, lon: 112.56028, locations facility: Xi'an Daxing Hospital, city: Xi'an, state: Shanxi, zip: 710000, country: China, geoPoint lat: 34.25833, lon: 108.92861, locations facility: Xi'an Gaoxin Hospital, city: Xi'an, state: Shanxi, zip: 710000, country: China, geoPoint lat: 34.25833, lon: 108.92861, locations facility: Zhejiang provincial people's hospital, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, locations facility: Fudan University Shanghai Cancer Center, city: Shanghai, zip: 200032, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False